Compare PPIH & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPIH | BNR |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.6M | 216.9M |
| IPO Year | N/A | 2020 |
| Metric | PPIH | BNR |
|---|---|---|
| Price | $32.33 | $29.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 92.6K | 19.1K |
| Earning Date | 12-12-2025 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $200,783,000.00 | $75,749,382.00 |
| Revenue This Year | $35.88 | $136.32 |
| Revenue Next Year | $6.64 | N/A |
| P/E Ratio | $18.83 | ★ N/A |
| Revenue Growth | ★ 30.74 | 5.56 |
| 52 Week Low | $8.81 | $2.18 |
| 52 Week High | $36.48 | $41.72 |
| Indicator | PPIH | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 52.53 | 50.03 |
| Support Level | $30.80 | $28.28 |
| Resistance Level | $33.64 | $34.26 |
| Average True Range (ATR) | 1.51 | 3.24 |
| MACD | 0.21 | -1.11 |
| Stochastic Oscillator | 57.31 | 15.56 |
Perma-Pipe International Holdings Inc is engaged in the manufacture and sale of products in the reportable segment of Piping Systems. The company engineers, designs, manufactures, and sells specialty piping systems and leak detection systems. Specialty piping systems include insulated and jacketed district heating and cooling piping systems for efficient energy distribution from central energy plants to multiple locations, primary and secondary containment piping systems for transporting chemicals, hazardous fluids, and petroleum products, and the coating and insulation of oil and gas gathering and transmission pipelines. It operates in the United States, Canada, the Middle East, Europe, India, and other countries.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.